rs10090104 - GPR20

Magnitude 2.2 · 1 study on file

Reported associations

• A genome-wide study of lipid response to fenofibrate in Caucasians: A joint analysis of the GOLDN and ACCORD studies - Unknown journal (n.d.) · Unknown authors · PubMed 27002377

  ABSTRACT: Background Fibrates are commonly prescribed for hypertriglyceridemia but also lower low-density lipoprotein cholesterol (LDL-C) and raise high-density lipoprotein cholesterol (HDL-C). Large inter-individual variation in lipid response suggests that some persons may benefit more than others and genetic studies could help identify those persons. Methods We conducted the first genome-wide association study (GWAS) of lipid response to fenofibrate using data from two well characterized clinical trials, the Genetics of Lipid Lowering Drugs and Diet Network (GOLDN) Study and the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Study. GWAS data from both studies were imputed to the 1000 Genomes CEU reference panel (phase 1). Lipid response was modeled as the log ratio of the po

Auto-generated from study metadata. AI-synthesised commentary is added when this entry is regenerated through content-service's LLM mode.